Penumbra

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. Its target markets include interventional neuroradiologists, neurosurgeons, neurologists, cardiologists, radiologists, and vascular surgeons. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Penumbra reports robust Q2 earnings, eyes growth amidst challenges

Penumbra's Q2 2024 earnings call showcased strong financial performance, operational efficiency, and a commitment to innovation and market access initiatives.
While facing challenges in revenue guidance reduction and competitive dynamics, the company's strengths in product performance and growth prospects position it well for the future.
Opportunities exist in leveraging innovation, addressing market challenges, and optimizing margins to drive sustained growth and competitiveness in the industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device (POD) system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004, and is headquartered in Alameda, CA.

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra and Asahi Intecc Co. will collaborate to introduce Penumbra's Indigo™ Aspiration System into the Japanese market upon regulatory approval.

Penumbra and Asahi Intecc Partner With Goal of Introducing Indigo™ System Including Lightning™ Intelligent Aspiration to Japan

Penumbra (PEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Penumbra (PEN) Surges 6.2%: Is This an Indication of Further Gains?

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra's RED® Reperfusion Catheters are now commercially available in Europe.

Penumbra Announces European Launch of RED® Reperfusion Catheters for Stroke Care

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced initial INSIGHT Registry data showing Penumbra's RED® reperfusion catheters were successful in removing all clot types. Additionally, results of sub-analyses of the COMPLETE study showed use of the Penumbra System is effective for acute ischemic stroke (AIS) patients with tandem lesions, as well as patients who are considered in the late window of treatment. The r

Latest Data Demonstrates Penumbra System and RED® Reperfusion Catheters Effective for Broad Stroke Care

Penumbra's operating performance has been up to par lately, including better-than-expected gross margins, but a rerating of growth med-tech has hit the shares harder than most. Management is trying to achieve a delicate balancing act between investing in REAL VR (a high-potential immersive technology platform for neuro and psychological rehab) and boosting near-term profitability.

Sector Rerating Has Cast A Shadow Over Penumbra

Penumbra, Inc. (NYSE:PEN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Jee Hamlyn-Harris - Head of Investor Relations Adam Elsesser - President and Chief Executive Officer Sandra Lesenfants - President, Interventional Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President, Strategy Conference Call Participants Lei Huang - Wells Fargo & Company Pito Chickering - Deutsche Bank David Rescott - Truist Securities Mike Matson - Needham & Company Brandon Vazquez - William Blair & Company Operator Good afternoon. My name is Angela, and I will be the conference operator today.

Penumbra, Inc. (PEN) CEO Adam Elsesser on Q2 2022 Results - Earnings Call Transcript

ALAMEDA, Calif. , Aug. 4, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2022.

Penumbra, Inc. Reports Second Quarter 2022 Financial Results

ALAMEDA, Calif. , July 27, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022.

Penumbra, Inc. to Present at the Canaccord Genuity 42nd Annual Growth Conference

Penumbra (PEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Penumbra (PEN) Surges 3.6%: Is This an Indication of Further Gains?

ALAMEDA, Calif. , July 7, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2022 after market close on Thursday, August 4, 2022 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 4, 2022

We think that Penumbra (NYSE: PEN), a medical devices company focused on interventional therapies, currently is a better pick compared to the Gap stock (NYSE: GPS), a specialty retailer selling casual apparel, accessories, and personal care products, despite it being the more expensive of the two.

Strong Revenue Trends And Better Prospects Make Penumbra Stock A Good Bet

Penumbra Inc (NYSE: PEN) reported Q1 sales that beat Street expectations, driven by Vascular upside, and reiterated its 2022 revenue guidance.  Wells Fargo lowered the price target to $265 from 321, which is equivalent to a 52.2% upside.

Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra's Price Target - Here's Why

Penumbra, Inc. (NYSE:PEN ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Jee Hamlyn-Harris – Investor Relations Adam Elsesser – Chairman and Chief Executive Officer Maggie Yuen – Chief Financial Officer Jason Mills – Executive Vice President-Strategy Conference Call Participants Larry Biegelsen – Wells Fargo Robbie Marcus – JPMorgan Joanne Wuensch – Citi David Rescott – Truist Securities Ryan Zimmerman – BTIG Mike Matson – Needham & Company Pito Chickering – Deutsche Bank Operator Hello, my name is Stephanie and I'll be your conference operator today. At this time, I would like to welcome everyone to the Penumbra, Inc. First Quarter 2022 Earnings Conference Call.

Penumbra's (PEN) CEO Adam Elsesser on Q1 2022 Results - Earnings Call Transcript

Penumbra (PEN) delivered earnings and revenue surprises of -116.67% and 4.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Penumbra (PEN) Reports Q1 Loss, Tops Revenue Estimates

ALAMEDA, Calif. , May 3, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2022.

Penumbra, Inc. Reports First Quarter 2022 Financial Results

ALAMEDA, Calif. , April 26, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10, 2022.

Penumbra, Inc. to Present at the Bank of America Securities 2022 Healthcare Conference

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc.'s Indigo Aspiration System with Lightning 7 and Lightning 12 have secured CE Mark and are now commercially available in Europe.

Penumbra Announces the European Launch of the Indigo® System With Lightning™ 7 and Lightning 12 Intelligent Aspiration

ALAMEDA, Calif. , April 5, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2022 after market close on Tuesday, May 3, 2022 at 4:30 PM Eastern Time.

Penumbra, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 3, 2022

ALAMEDA, Calif.--(BUSINESS WIRE)---- $PEN #penumbra--Penumbra, Inc. introduces the REAL® Immersive System y-Series™ with significantly more activities and experiences.

Penumbra Introduces Next Generation REAL® y-Series™, Expanding Virtual Reality Healthcare Platform

ALAMEDA, Calif. , March 28, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022.

Penumbra, Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference

Clover Health Investments

Vir Biotechnology

Looking for small healthcare companies with huge revenue opportunities? Try these.

These 3 Stocks Aren't Large Caps Yet, but They Each Could Make $1 Billion in Sales in 2022

The stock price of Penumbra, a medical devices company focused on interventional therapies, has seen a 16% fall in a month, while it was down 10% last week. The company reported mixed Q4 results last month, with revenue of $204 million and adjusted EPS of $0.10 per share, compared to the consensus.

Down 16% In A Month, Will Penumbra Stock Rebound?

Penumbra has been posting strong revenue growth numbers, but the Street has not been rewarding the shares.

Penumbra A Little Beaten Down Despite Strong Growth Opportunities

Penumbra Inc (NYSE: PEN) posted Q4 FY21 revenue of $204 million, +22.2% Y/Y (up 23% in constant currency), beating the consensus of $194.30 million. Revenue from sales of vascular products grew 30.4% (31.1%) to $113.6 million.

Penumbra Posts Mixed Bag Q4 Results, Reports Topline Growth Of 22%

The average of price targets set by Wall Street analysts indicates a potential upside of 40.2% in Penumbra (PEN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

News for Penumbra Stock (PEN)